Fresenius SE & Co KGaA (FRA:FRE) Given a €52.00 Price Target at Sanford C. Bernstein

Sanford C. Bernstein set a €52.00 ($60.47) price target on Fresenius SE & Co KGaA (FRA:FRE) in a research report sent to investors on Tuesday, Borsen Zeitung reports. The brokerage currently has a neutral rating on the stock.

FRE has been the topic of a number of other reports. JPMorgan Chase & Co. set a €59.40 ($69.07) target price on shares of Fresenius SE & Co KGaA and gave the stock a buy rating in a research note on Tuesday, November 5th. Morgan Stanley set a €50.00 ($58.14) target price on shares of Fresenius SE & Co KGaA and gave the stock a neutral rating in a research note on Monday, September 30th. Credit Suisse Group set a €50.00 ($58.14) target price on shares of Fresenius SE & Co KGaA and gave the stock a neutral rating in a research note on Friday, October 18th. Jefferies Financial Group set a €43.00 ($50.00) target price on shares of Fresenius SE & Co KGaA and gave the stock a neutral rating in a research note on Tuesday, October 29th. Finally, Warburg Research set a €65.00 ($75.58) target price on shares of Fresenius SE & Co KGaA and gave the stock a buy rating in a research note on Tuesday, October 29th. Ten research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The stock currently has an average rating of Hold and a consensus price target of €55.84 ($64.94).

FRE stock traded down €0.27 ($0.31) during trading on Tuesday, reaching €47.72 ($55.49). 1,115,381 shares of the stock were exchanged. The business has a 50 day moving average price of €44.42 and a 200-day moving average price of €45.90. Fresenius SE & Co KGaA has a 1 year low of €60.16 ($69.95) and a 1 year high of €80.00 ($93.02).

Fresenius SE & Co KGaA Company Profile

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Further Reading: Most Volatile Stocks – What Investors Need to Know to Maximize ROI

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.